277 related articles for article (PubMed ID: 36135270)
1. Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers-An Overview.
Mathiyalagan R; Kariyarath Valappil A; Yang DC; Kang SC; Thambi T
Gels; 2022 Sep; 8(9):. PubMed ID: 36135270
[TBL] [Abstract][Full Text] [Related]
2. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling.
Paluncic J; Kovacevic Z; Jansson PJ; Kalinowski D; Merlot AM; Huang ML; Lok HC; Sahni S; Lane DJ; Richardson DR
Biochim Biophys Acta; 2016 Apr; 1863(4):770-84. PubMed ID: 26844774
[TBL] [Abstract][Full Text] [Related]
3. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
4. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
[TBL] [Abstract][Full Text] [Related]
5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
6. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
8. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy.
Yajima I; Kumasaka MY; Thang ND; Goto Y; Takeda K; Yamanoshita O; Iida M; Ohgami N; Tamura H; Kawamoto Y; Kato M
Dermatol Res Pract; 2012; 2012():354191. PubMed ID: 22013435
[TBL] [Abstract][Full Text] [Related]
9. Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer.
Pappalardo F; Russo G; Candido S; Pennisi M; Cavalieri S; Motta S; McCubrey JA; Nicoletti F; Libra M
PLoS One; 2016; 11(3):e0152104. PubMed ID: 27015094
[TBL] [Abstract][Full Text] [Related]
10. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract][Full Text] [Related]
11. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
12. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
13. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.
Meier F; Schittek B; Busch S; Garbe C; Smalley K; Satyamoorthy K; Li G; Herlyn M
Front Biosci; 2005 Sep; 10():2986-3001. PubMed ID: 15970553
[TBL] [Abstract][Full Text] [Related]
14. Signal transduction in human cutaneous melanoma and target drugs.
Uzdensky AB; Demyanenko SV; Bibov MY
Curr Cancer Drug Targets; 2013 Oct; 13(8):843-66. PubMed ID: 23675881
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
16. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
Wee S; Jagani Z; Xiang KX; Loo A; Dorsch M; Yao YM; Sellers WR; Lengauer C; Stegmeier F
Cancer Res; 2009 May; 69(10):4286-93. PubMed ID: 19401449
[TBL] [Abstract][Full Text] [Related]
17. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
McCubrey JA; Steelman LS; Abrams SL; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM
Leukemia; 2008 Apr; 22(4):708-22. PubMed ID: 18337766
[TBL] [Abstract][Full Text] [Related]
18. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
19. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
20. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
